Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.56 |
| ▸ | ERN1 | O75460 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7842649 | 0.87 | CYP19A1 (0.43) | CYP19A1ERN1SIGMAR1 | |
| SCHEMBL7842654 | 0.87 | CYP19A1 (0.43) | CYP19A1ERN1SIGMAR1 | |
| SCHEMBL7842652 | 0.87 | CYP19A1 (0.43) | CYP19A1ERN1SIGMAR1 | |
| SCHEMBL7004961 | 0.87 | CYP19A1 (0.43) | CYP19A1ERN1SIGMAR1 | |
| SCHEMBL7004957 | 0.87 | CYP19A1 (0.43) | CYP19A1ERN1SIGMAR1 | |
| SCHEMBL8152835 | 0.84 | CYP19A1 (0.58) | CYP19A1ERN1MMP2ANPEPSIGMAR1 | |
| SCHEMBL2380958 | 0.79 | PTPN1 (0.49) | CYP19A1MMP2ANPEPPTPN1 | |
| SCHEMBL30987621 | 0.79 | PTPN1 (0.49) | CYP19A1MMP2ANPEPPTPN1 | |
| SCHEMBL2380961 | 0.79 | PTPN1 (0.49) | CYP19A1MMP2ANPEPPTPN1 | |
| SCHEMBL2836619 | 0.79 | PTPN1 (0.49) | CYP19A1MMP2ANPEPPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030195196-A1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
| EP-1109811-B1 | PYRROLOBENZODIAZEPINES | SPIROGEN LTD (GB) | 2003-08-06 | — | — | EP | disclosed |
| US-6562806-B1 | A prodrug may be converted into an antitumour agent under the influence of an enzyme that is linked to a monoclonal antibody so that it can bind to a tumour associated antigen | SPIROGEN LIMITED (GB) | 2003-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195196-A1 | Pyrrolobenzodiazepines | CNR2, CNR1, HRH3 | CYP19A1 4672/4885ERN1 3848/4885MMP2 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.